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Summary The incidence of B cell leukaemia in 186 consecutive untreated patients with histologically defined
B cell neoplasms is described. The lymphomas were classified by the Kiel convention. B cell leukaemia in the
context of this paper refers to the situation where a neoplastic clone of B cells in the blood greatly
outnumbers normal blood B cells. It is defined as an absolute blood B cell count >0.75 x 10911 where either
>90% B cells express K immunoglobulin light chains or >80% express A light chains. This was found in
several patients where the total blood lymphocyte count was within normal limits. All patients with diffuse
lymphocytic lymphoma with the histological appearances of B cell chronic lymphocytic leukaemia (ML-
BCLL) were found to have B cell leukaemia. However, more than half these patients had blood B cell counts
< 10 x 1091-. B cell leukaemia was also a feature in 33% of patients with follicle centre cell tumours and
33% of those with lymphoplasmacytoid tumours. B cell leukaemia was not detected in 34/35 patients with
myelomatosis. The 35th patient had plasma cell leukaemia. Only 3/22 patients with high grade lymphoma had
B cell leukaemia. In the three principal tumour types associated with B cell leukaemia p+5 was the most
common immunoglobulin heavy chain phenotype. Spontaneous mouse red cell rosette formation also
characterised leukaemic B cells in these three groups but high proportions of mouse rosetting cells were seen
only in association with ML-BCLL. None of 4 cases of prolymphocytic leukaemia showed mouse red cell
rosetting. HLA-DR a chain was found on the leukaemic cells of all patients except one with ML-BCLL. B cell
lymphopenia was a frequent finding in all histological groups in those patients who did not have B cell
leukaemia.
Lymphoproliferative disorders commonly arise in
cells representative of the various differentiation
stages of B cells. Chronic lymphocytic leukaemia
(CLL), for example, most obviously involves
recirculating B cells. While myelomatosis and
lymphoplasmacytoid tumours characteristically
consist of antibody-secreting cells, follicle centre cell
(FCC) lymphomas appear to represent tumours of
those B cells found in germinal centres-
centroblasts and centrocytes. These neoplasms may
involve more than one maturation stage of B cells
(Galton & MacLennan 1982). This is shown in
CLL where a proportion of patients have
paraproteins derived from the neoplastic clone
(Leonard et al., 1979). Equally B cell leukaemia,
not obviously different from that seen in CLL may
occur in some patients with FCC lymphomas
(Galton et al., 1978; Garrett et al., 1979). The
purpose of this report is to indicate the incidence of
B cell leukaemia in a large consecutive series of
untreated patients with histologically defined B cell
neoplasia. It will be shown that B cell leukaemia
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varies considerably in its incidence with different
histological types of lymphoma. The report also
indicates that in aleukaemic patients, B cell
lymphopenia is a common finding.
Materials and methods
Patients
Blood was sent to the Department of Immunology
at Birmingham from patients for diagnostic
lymphocyte phenotype analysis. Strenuous efforts
were made in all cases, irrespective of blood
lymphocyte findings, to review tissue biopsy
material where this was available. This report
consists of the analysis of blood lymphocytes in 186
consecutive and untreated patients where
histological diagnosis was obtained.
Histopathy and other diagnostic criteria
All biopsy material was examined by both E.L.
Jones and I.C.M. MacLennan. Classification was
made according to the Kiel convention of
histopathologists (Lennert 1978). Tissues were
processed using conventionally fixed material and
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paraffin sections stained with haematoxylin and
eosin, reticulin and methyl green pyronin. Immuno-
histological and histochemical techniques were
carried out on frozen and conventionally processed
sections in a proportion of cases to confirm the
presence of monoclonal B cell involvement or
exclude non-B cell tumours. Patients with
myelomatosis were diagnosed by having at least
two of the following features: (a) monoclonal
plasma cell infiltrate in the bone marrow (b)
osteolytic lesions (c) a paraprotein in the blood or
urine. We are grateful to Professor Jacobs of the
Welsh National School of Medicine, Cardiff, for
submitting blood from a number of patients with
myelomatosis.
Lymphocyte surface marker studies
The methods were, in general, as described by Ling
& MacLennan (1981). Briefly, lymphocytes were
separated from heparinised blood by centrifugation
through Ficoll-Triosil They were then incubated
overnight at 37°C in RPMI 1640 with 10% foetal
bovine serum to remove cytophilically bound
protein. Phagocytic cells contaminating this
preparation were identified by the addition of heat-
killed rhodamine-labelled yeasts previously
opsonised by incubation with 20% fresh sheep
serum. This mononuclear cell preparation was then
used for identification of surface membrane
antigens by the direct antibody rosette technique.
This involved the use of ox red cells variously
coated with either an IgG preparation of sheep
antisera or mouse monoclonal antibodies against a
variety of antigens found on the surface of human
lymphocytes. Sheep polyclonal antibodies were used
to detect 6, a, y and £ heavy chains of immuno-
globulins. The following monoclonal antibodies
were used: AF6 against u immunoglobulin heavy
chains; 6el against K and C4 against A immuno-
globulin light chains. These monoclonal antibodies
were produced in the Department of Immunology,
University of Birmingham (Lowe et al., 1981). The
polyclonal antisera were produced in the Immuno-
diagnostic Research Laboratory of the same
department. In addition monoclonal antibody
UCHT-1 which detects the T3 antigen, a pan-
peripheral T associated molecule, was a kind gift
from Dr Peter Beverley (Beverley & Callard, 1981).
An anti-HLA-DR a chain antibody 19/48 was a
kind gift from Dr G. Brown. Peanut agglutinin,
prepared by Dr Raykundalia as described by Rose
et al. (1981), was also coupled to ox red cells.
The direct antibody rosette test is a very sensitive
assay for measuring surface membrane antigens. It
is particularly useful for detecting the low levels of
surface membrane immunoglobulin (SmIg)
classically associated with CLL (Dhaliwal et al.,
1978). This is reflected in the results reported in this
paper where all patients with ML-BCLL were
shown to have B cell-leukaemia. However, the
technique is relatively insensitive for demonstrating
the amount of SmIg on cells. Consequently we were
unable to provide data on the quantity of Ig
expressed on the surface from the results of this
study as has been done, for example, by Koziner et
al. (1980).
The number of lymphocytes spontaneously
binding sheep red cells and mouse red cells was also
determined (Stathopoulos & Elliott, 1974).
Lymphocytes were prepared as above. Rosettes
were made by centrifuging the lymphocyte and red
cell suspensions at 250g for 5min and incubating
the pellet at 4°C for 3h. The rosettes were
resuspended gently by placing on a 15rpm rotor.
The cells were not pre-treated in this study with
neuraminidase, a procedure which stabilises
spontaneous rosettes (Bentwich et al., 1973).
However, sheep red cells were pretreated with 2%
S-2-Amino-ethylisothiouronium salt (AET) for
15min to increase the strength of rosettes (Kaplan
& Clark, 1974).
Absolute lymphocyte numbers were calculated
from a total white cell count (blood collected in
sequestrene) and a differential count performed on
a blood sample collected at the same time as that
used for marker studies. Phagocytic cells were
identified by their ingestion of rhodamine-labelled
opsonised yeasts which were distinguishable under a
fluorescence microscope from the leucocyte nuclei
which were labelled with acridine orange. The
proportions of non-phagocytic mononuclear cells
forming rosettes was determined in suspension in
counting chambers.
Results
B cell leukaemia
The number of blood lymphocytes expressing SmIg
was determined in 186 untreated patients with
histologically classified B cell neoplasia and 15
healthy controls. These values are plotted against
the ratio of blood lymphocytes expressing kappa to
those expressing lambda in Figure 1 (a-f). The
absolute B cell numbers in the healthy control
group fell within the range of 0.12-0.7 x 1091-1.
The K: A ratio for the group ranged between 2.67
and 0.8. Different histopathological groups of B
cell neoplasms showed marked differences from the
normal and from each other. In ML-BCLL all but
one of the patients showed evidence of B cell
leukaemia, as defined by having more than
0.75 x 109 B lymphocytes I` with either >90%
expressing kappa or >80% expressing lambda.B CELL LEUKAEMIA IN ADULT B CELL NEOPLASIA 187
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Figure 1 a-f. The K:A ratio of B cells in the blood in relation to total numbers of B cells in patients with
various B cell neoplasms. Dotted lines=upper (9) and lower (0.25) limits of Ki:2 ratio. The box indicates the
limits of normality. The diagnostic groups were as follows: a= 15 healthy controls; b =22 cases with high
grade tumours; c= 19 cases with lymphoplasmacytoid lymphoma; d =65 cases with FCC tumours; e=35 cases
of myelomatosis; f=42 cases with ML-BCLL.
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These represent K: . ratios of 9 and 0.25
respectively. Twenty-one of these cases had a B
lymphocyte count <10 x IO'9-l, and in three cases
absolute lymphocyte counts were within the normal
adult range i.e. <3.5 x IO'1- . The main exception
was one case where the number of cells with SmIg
was 51 x 1Q91-1; there were 80% cells expressing
kappa and 20% expressing lambda. Unfortunately a
repeat sample was not available from this case to
determine if two clones were present or whether the
result was due to passive binding of extrinsic Ig
which had resisted removal following overnight
incubation of the lymphocytes at 37°C.
By contrast, B cell leukaemia was not a feature of
myelomatosis. In only one case of the 35 patients
with this disease studied was there a dominant
neoplastic clone of cells with SmIg. These cells were
morphologically identifiable as plasma cells. In
eleven of the patients with myelomatosis there was
B cell lymphopenia.
In patients with low grade FCC tumour a third
pattern was apparent. Sixty-five patients were
included in this group. Fifty-nine had mixed
centrocytic-centroblastic lymphoma and 6
centrocytic lymphoma. Eighteen of the patients had
B lymphopenia. Twenty of the group had overt B
cell leukaemia. Most of these patients with B cell
leukaemia had B lymphocyte counts of
<10 x iO1 F' and eight had total lymphocyte
counts within the normal range. The leukaemic B
cells in these patients, in general, resemble the
morphological spectrum associated with CLL.
Although centrocytes were identifiable in the blood
in a proportion of both aleukaemic and leukaemic
patients they were usually present as a minor
fraction. Occasionally patients were seen where the
majority of leukaemic cells were centrocytes. Of the
six patients with pure centrocytic lymphoma
analysed, one had B cell leukaemia.
Lymphoplasmacytoid tumours were associated
with a similar spectrum of blood B cell profiles to
that seen in FCC tumours; i.e. about a third had B
cell leukaemia, a third had B cell lymphopenia and
a third had a normal number of B cells.
In high grade lymphoma, B cell lymphopenia was
a feature in over half the cases. Three of the 22
patients in this group had B cell leukaemia. This
group comprised 9 patients with centroblastic
lymphoma, 5 with immunoblastic lymphoma and 8
unclassifiable cases with high grade lymphoma.
Ig isotypes on leukaemic B cells in patients from the
different histopathological groups
Results are shown in Table I. The ratio of cases
of kappa-expressing leukaemias to those expressing
lambda is 1.52 and this is reflected in the histo-
pathological groups where sufficient numbers are
available for meaningful analysis. The most
common heavy chain isotype pattern is of p and 6
but y and a were encountered either alone or in
association with p and 6; there were 9 cases with
triple heavy chain expression. One patient expressed
kappa light chain without detectable heavy chain.
Evidence supporting the conclusion that leukaemic
B cells from this patient are indeed expressing free
kappa light chains was provided by the reactivity of
the leukaemic cells with anti-free K light chain
antibodies. Details of this finding will be presented
elsewhere. No Ig profile distinguishing B cells in
any one histopathological group was observed.
Other markers
(i) MRBC binding. It will be seen from Table II
that rosetting with mouse cells was a feature of a
proportion of leukaemic B cells irrespective of
histopathological group. Occasional patients
without overt B cell leukaemia had >5% blood
lymphocytes rosetting. However, high percentages
of mouse rosettes were characteristic of the ML-
BCLL group only (Table II).
(ii) Peanut agglutinin binding. Of 45 patients with
FCC tumour analysed for this marker, 10 had more
than 5% PNA positive cells. Five of these did not
have overt B cell leukaemia. Occasional patients
with other types of B cell tumour also had >5%
PNA positive cells including the patient with
plasma cell leukaemia (Figure 2).
(iii) HLA-DR alpha chain expression. Cells from
only one of 37 patients with diffuse lymphocytic
lymphoma failed to express this antigen. It was
expressed on the neoplastic B cells found in the
blood in all of the 14 cases with FCC tumours.
Non-B cells in patients with B cell lymphopenia
The number of cells binding SRBC and anti-T3
antigen-coated ox cells was analysed in relation to
the number of B cells in aleukaemic patients to see
if the absolute B cell lymphopenia, which was a
feature of many patients in this series, was
associated with reduced T cell numbers. Of the 18
patients with follicle centre cell lymphoma and B
cell lymphopenia (<0.1 x 10'11), eleven were
judged to be T lymphopenic in that they had fewer
than 0.6 x 109-1 1 cells binding SRBC. In high
grade lymphoma 7 out of 11 B lymphopenic
patients were T lymphopenic. T cell lymphopenia
was seen in 3/11 patients with B lymphopenia in
myelomatosis and in 4/7 with lymphoplasmacytoid
lymphoma. Overall 53% of 47 patients with B cell
lymphoma had reduced number of T cells. Only 4
cases of selective T cell lymphopenia were identifiedB CELL LEUKAEMIA IN ADULT B CELL NEOPLASIA 189
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leukaemia.
The incidence of lymphopenia and lymphocytosis
in patients without B cell leukaemia is shown in
Table III. Only 3/108 patients in this table had
lymphocyte counts above the 95 percentile for
adults. Lymphopenia, however, was a common
feature of all patient groups. Table III also shows
the frequency with which patients presented with
null cell numbers >0.5 x 109- 1. This was no
greater in the non-Hodgkin's lymphoma groups
than in a healthy adult control group assessed using
the same techniques during the period of this study.
The incidence of raised null cell numbers was
slightly higher in myelomatosis compared to that in
healthy controls. However, this difference was not
significant (P>0.05 Wilcoxan sum of ranks test).
Discussion
Immunological methods have identified several
patientswith a Bcell leukaemiawhichwouldnothave
been suspected from conventional haematological
tests. Diffuse lymphocytic lymphoma with the
histological appearances in secondary lymphoid
organs associated with B-CLL (ML-BCLL) is most
frequently associated with overt haematologically
recognisable lymphocytic leukaemia. This is much
less frequently a feature in other B cell neoplasms.
It has been recognised, however, that a proportion
of these patients at some stage of their illness
develop a B cell leukaemia indistinguishable from
that associated with CLL. Galton et al. (1978)
followed up 75 patients with follicle centre cell
lymphoma over a period of 20 years and found that
several patients in this group had a lymphocytosis
resembling that found in CLL. Seventeen out of 75
cases in his study had lymphocyte counts ranging
from 5-30 x109 1 and in 8 others, although the
count was <5 x1091-1, the bone marrow showed
lymphocytic infiltration. Cells with notched or
cleaved nuclei were seen in the peripheral blood of
8 of the cases seen in their study. Garrett et al.
(1979) studied 63 patients with non-Hodgkin's
lymphoma all with lymphocyte counts below
6 x 1091 1 and correlated peripheral blood findings
with the histology using inbalance in kappa/lambda
ratio to determine the presence of an abnormal
clone of lymphocytes. In their study, 81% of cases
of well differentiated diffuse lymphoma, 66% of
poorly differentiated diffuse lymphoma and 22% of
diffuse histiocytic lymphoma had cells of the
abnormal clone in the peripheral blood. Gajl-
Peczalska et al. (1975) studied 64 untreated and 23
treated patients with non-Hodgkin's lymphoma and
found B cell leukaemia in 5/31 patients with poorly
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Table II The proportion of lymphocytes binding mouse red cells in different histopathological
groups
Number ofcases in groups based on the
percentage ofblood lymphocytesforming
Total number rosettes with mouse red cells
Diagnosis ofcases <5% 5-29% 30-49% >50%
Follicle centre cell tumours
without leukaemia 45 38 7 0 0
Follicle centre cell tumours
with leukaemia 20 8 6 5 1
MC-BCLL 42 7 14 11 10
Lymphoplasmacytoid cell
without leukaemia 13 10 3 0 0
Lymphoplasmacytoid cell
with leukaemia 5 1 3 1 0
High grade lymphomas 22 22 0 0 0
Myelomatosis 35 30 5 0 0
Prolymphocytic leukaemia 4 4 0 0 0
The technique of mouse erythrocyte rosetting is described in the methods and did not involve
neuraminidase-treatment ofcells.
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Figure 2 Incidence of peanut agglutinin positivity in the various B cell neoplasms in relation to total number
ofBcellsintheblood. FCC=folliclecentrecelllymphoma;DLL =ML-BCLL;LPC=lymphoplasmacytoidtumour;
MM=myelomatosis; HGL =high grade lymphoma; L =leukaemic; NL=non-leukaemic; PNA=peanut
agglutinin. (0)=PNA +ve cells <5% blood kymphocytes; (0)= PNA +ve cells >5% blood lymphocytes.
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Table III The incidence of lymphocytosisa, lymphopeniae and increased null cellh numbers in patients
without B cell leukaemia
Number (%) with Number (%) with
Histopathological Total Number (%) with Number (%) with null cell count null cell count
group studied lymphocytosis? lymphopeCiae >0.5 <1 x 1091 >1 x 1091`
Low grade FCC 45 lb (2) 16 (36) 9 (20) 0
LPC lymphoma 13 0 4 (30) 4 (30) 0
High grade lymphoma 19 iC (5) 10 (52) 2 (11) 0
Myelomatosis 31 Id (3) 6 (16) 12 (39) 2f (6)
Healthy controls 15 0 0 4 (26) 1g (7)
aWhere blood lymphocyte count >3.5 x 1091.
b4.3 x 109 1
C4.2x 1091*
d4.3 x 10 1;
'Where blood lymphocyte count <1 x 1091.
f1.4 and 1.9 x 1091-1.
l.0x 1091-.
hNull cell numbers are calculated as the total lymphocyte count -(the sum of the number of cells forming
rosettes with SRBC, anti K-coated ox red cells and anti A-coated ox red cells).
differentiated nodular lymphoma and in 5/36
patients with poorly differentiated diffuse
lymphoma. In a recent abstract Swerdlow et al.
(1983) reported that 8/17 patients with centrocytic
lymphoma had lymphocytosis. If this lymphocytosis
was secondary to B cell leukaemia then the
incidence of this phenomenon in pure centrocytic
lymphoma is higher than that found in this study
i.e. I of 6 patients. We have, however, noticed B
cell leukaemia develQping in treated patients with
follicle centre cell tumours as was also noted by
Galton et al. (1978). Consequently, study of
patients diagnosed some time previously may reveal
a higher incidence of B cell leukaemia.
Our studies, based on K:) ratios, do not provide
evidence for the presence in the blood of dominant
IgM- and IgD-bearing lymphocytes of the
neoplastic clone in myelomatosis. Pettersson et al.
(1979, 1980) and Mellstedt et al. (1982) have noted
cases of myelomatosis where there were substantial
numbers of lymphocytes bearing the same Ig
isotypes as the paraprotein. They observed this
developing in patients as a late phenomenon
associated with poor prognosis. However, these
workers, in most cases of myelomatosis they
studied, failed to demonstrate B cell leukaemia. This
does not mean to say that small numbers of B cells
or cells of the neoplastic clone are not present in
the blood but that these cells are not usually
present in sufficient numbers to dominate non-
malignant B cells. In this respect myelomatosis
differs from ML-BCLL, lymphoplasmacytoid
lymphoma and low grade FCC lymphoma.
Kubagawa et al. (1980), using anti-idiotype reagents
found small numbers of cells at the B cell and even
pre-B&'cell stage in myelomatosis, which bore the
idiotype of the myeloma protein. However, it has
been demonstrated in experimental animals that the
production of non-neoplastic B cells from pre-B
cells bearing particular VH immunoglobulin
epitopes can be induced by transfer of antibody
with these epitopes (Coutino et al., 1980); The
possibility that such an evocative process occurs in
myelomatosis has not been excluded. Preud'homme
et al. (1977) have described the appearance of T
cells in the blood of a patient with myelomatosis
bearing epitopes on non-immunoglobulin molecules
common with VH determinants on the paraprotein.
This also may represent an example of expansion of
non-neoplastic cells via the idiotype network.
(Rubinstein et al., 1982). In only one of the cases of
myelomatosis which we studied (excluding the case
of plasma cell leukaemia) was there lymphocytosis.
In this patient the rise was associated with an
increase in blood null cell members to 1.9 x 1091
(Table III).
It is relevant to consider how neoplasms with
associatedc B cell leukaemia can exist at more than
one stage of differentiation. One hypothesis is that
neoplastic transformation in patients with B cell
leukaemia occurs at the virgin B cell level
(Johnstone, 1982). Alternatively, the neoplastic
transformation may take place in an activated B
cell i.e. an immunoblast. These cells can give rise to
both more mature forms and memory B cells which
form part of the recirculating small B cell pool.
Memory B cells have been shown to develop from
a small proportion of immunoblasts in efferent
lymph (Howard, 1972). Equally there is good
evidence that centroblasts of germinal centres may192 ABDUL-CADER et al.
give rise to memory small B cells (Klaus et al.,
1980). This finding opens the possibility that the
leukaemia associated with follicle centre cell
tumours could reflect the physiological production
of memory B cells from germinal centres. Similarly
it can be argued plausibly that patients with
lymphoplasmacytoid tumours and B cell leukaemia
have neoplastic immunoblasts capable of generating
three cell types. i.e. (1) self replication (2) memory
B cell formation and (3) lymphoplasmacytoid cell
formation. Presumably the neoplastic process has
resulted in loss of a self-limiting component in the
first of these compartments. In the case of
myelomatosis it would appear that the clonogenic
cells are capable of self replication and bone
marrow seeking plasma cell formation but lack the
capacity to generate memory B cells.
Apart from SmIg, the MRBC (mouse) and HLA-
DR markers have been found useful in diagnosis of
B cell neoplasms. Our findings confirm that the
most prominent binding of mouse red cells is seen
in CLL (Catovsky et al. 1979 and Koziner et al.
1977). Catovsky et al. (1979) report higher
proportions of cells binding to mouse cells in B
CLL than we have found. This probably reflects
the use of neuraminidase pretreatment of cells
before rosetting which has been reported as
selectively increasing mouse rosettes in CLL
(Catovsky et al., 1976). Mouse rosette binding has
been reported not to be a feature of
prolymphocytic leukaemia (Catovsky et al., 1979).
However, Koziner et al. (1980) reported four cases
with the features of prolymphocytic leukaemia
whose neoplastic cells did bind mouse red cells. In
the current study mouse rosetting was not found in
the four cases of B-prolymphocytic leukaemia
studied. The spectrum of patients studied by us
with ML-BCLL probably includes a higher
proportion of patients with low lymphocyte count
than most previous studies which tend to
concentrate on classical CLL with blood
lymphocyte counts >10 x 1091-'. We were unable
to identify any feature using the marker range
reported in this study which distinguished the
phenotype of low and high blood lymphocyte count
ML-BCLL. The HLA-DR marker is useful in that
B cells at the late differentiation stage, including
lymphoplasmacytoid cells, are DR negative whereas
cells at the B cell stage, whether pre- or post-
antigen stimulation, are DR positive. Peanut
agglutinin hgs been reported to bind to germinal
centre cells (Rose et al., 1981). However, this has
not proved in our hands to be a useful marker for
B cell leukaemia associated with FCC tumours.
This finding supports the concept that leukaemic B
cells in this disease, in many cases, represent a
distinct maturation phase from the tumour cells
found in secondary lymphoid organs. It is arguable
whether they are a precursor or a derivative of the
follicle centre cells. Positive results for cells bearing
PNA receptors have been observed in acute
lymphoblastic leukaemia (Levin et al., 1980) and
for a blood cell subset which lacks HLA (Ballet,
1980). PNA has also been reported to be a marker
for normal and leukaemic cells of the monocyte
lineage (O'Keefe and Ashman, 1982).
Total lymphopenia as well as B cell lymphopenia
was found in a significant proportion of patients in
most of the different histopathological groups of B
cell lymphoma. This was most obvious in patients
with FCC lymphoma or high grade lymphoma
where one-third and over half of the respective
cases had B cell lymphopenia at presentation. The
significance of this lymphopenia in B cell neoplasia
is not known but it has been noted by other
investigators (Bums et al., 1979; Dillman et al.,
1981). It is sufficiently common to be a diagnostic
pointer to non-Hodgkin's lymphoma. However, it is
also associated with other disorders such as
primary immunodeficiency, which may present with
features resembling lymphoma.
The authors wish to thank their many colleagues in the
West Midlands Health region who have assisted in this
study. A. Cader is an Leukaemia Research Fund training
fellow. P. Richardson is supported by the West Midlands
Regional Health Authority research fund.
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